|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1992
gptkb:FDA
|
|
gptkbp:atc_code
|
N05 C
|
|
gptkbp:brand
|
gptkb:Ambien
gptkb:Edluar
gptkb:Intermezzo
Zolpimist
|
|
gptkbp:chemical_formula
|
C19 H21 N3 O
|
|
gptkbp:class
|
sedative-hypnotic
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
sleep apnea
severe respiratory insufficiency
|
|
gptkbp:dependency_risk
|
low to moderate
|
|
gptkbp:discovered_by
|
Searle
|
|
gptkbp:dosage_form
|
10 mg
5 mg
|
|
gptkbp:duration
|
short-term use
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
sublingual tablet
oral spray
|
|
gptkbp:has_tradition
|
possible with prolonged use
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zolpidem Tartrate
|
|
gptkbp:interacts_with
|
gptkb:beer
CYP3 A4 inhibitors
|
|
gptkbp:legal_status
|
prescription-only
|
|
gptkbp:lifespan
|
2.5 hours
|
|
gptkbp:marketed_as
|
gptkb:Sanofi
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:depression
dizziness
headache
nausea
allergic reactions
confusion
memory loss
drowsiness
behavioral changes
hallucinations
sleepwalking
agitation
|
|
gptkbp:structure
|
imidazopyridine
|
|
gptkbp:suitable_for
|
gptkb:children
pregnant women
elderly patients
breastfeeding women
|
|
gptkbp:symptoms
|
anxiety
insomnia
tremors
|
|
gptkbp:used_for
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:Zolpidem
|
|
gptkbp:bfsLayer
|
6
|